CFG920

CFG920 is an orally active, nonsteroidal small molecule that acts as a reversible dual inhibitor of cytochrome P450 enzymes CYP17A1 (steroid 17-alpha-hydroxylase/C17,20 lyase) and CYP11B2 (aldosterone synthase). By inhibiting CYP17A1 in the testes and adrenal glands, it suppresses androgen production and may decrease androgen-dependent growth signaling in prostate cancer cells. Inhibition of CYP11B2 affects mineralocorticoid synthesis. Developed by Novartis in collaboration with Aurigene for the treatment of metastatic castration-resistant prostate cancer (mCRPC), especially in patients who are abiraterone-naive or abiraterone-resistant. Unlike steroidal inhibitors such as abiraterone acetate (Zytiga), CFG920 is nonsteroidal and reversibly inhibits its targets[1][5][6][7].

Other names

1-(2-chloro-4-pyridinyl)-3-(4-methyl-3-pyridinyl)-2-imidazolidinone2-imidazolidinone, 1-(2-chloro-4-pyridinyl)-3-(4-methyl-3-pyridinyl)